医药行业周报：本周医药上涨6.4%，NMPA加强药品受托生产监管，司美格鲁肽前三季度销售超200亿美元

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, rating it as "Overweight" [2][3]. Core Insights - The pharmaceutical sector saw a weekly increase of 6.4%, outperforming the Shanghai Composite Index, which rose by 5.5% [3][4]. - The overall valuation of the pharmaceutical sector stands at 29.2 times PE for 2024E, ranking 7th among 31 primary industries [4][7]. - Key events include the NMPA's strengthened supervision of entrusted drug production, which encourages the production of innovative and urgently needed drugs while restricting low-value, highly homogeneous drugs from being produced this way [7][8]. - The National Health Commission aims to enhance geriatric medical service capabilities, targeting that by the end of 2027, 80% of secondary and higher-level hospitals will have established geriatrics departments [8]. - The report highlights significant sales figures for semaglutide, with over $20 billion in sales in the first three quarters of 2024, indicating strong market demand [9]. Summary by Sections Market Performance - The pharmaceutical index increased by 6.4% this week, ranking 14th among 31 sub-industries [3][4]. - Various sub-sectors showed positive performance, with hospitals leading at a 13.1% increase, followed by medical R&D outsourcing at 8.7% [4][5]. Key Events - The NMPA's announcement on November 5 emphasizes the need for enhanced supervision in drug production, particularly for innovative and essential drugs [7]. - The National Health Commission's initiative to improve geriatric services aims for a significant increase in the establishment of geriatrics departments in hospitals by 2027 [8]. - The submission of a new drug application for舒沃替尼 to the FDA marks a significant milestone for Chinese-origin targeted lung cancer therapies [8]. Sales Performance - Novo Nordisk reported that semaglutide contributed approximately $20.29 billion in sales during the first three quarters of 2024, reflecting a robust growth trajectory [9].